Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models

Forschungsstelle

INNOSUISSE

Projektnummer

104.824.1 IP-LS

Projekttitel

Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models

Projekttitel Englisch

Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models
Kurzbeschreibung (Englisch)	Evaluation of novel targeting strategies to deliver engineered protein therapeutics in relevant in vitro and in vivo osteoarthritis models
Abstract (Deutsch)	Osteoarthritis(OA) is a degenerative joint disease for which no disease-modifying drugs are available. Philochem AG and ETH Zurich will develop novel immunocytokines and evaluate delivery and screening systems to select the best candidate for the clinical development of a groundbreaking OA therapy.
Abstract (Englisch)	Osteoarthritis(OA) is a degenerative joint disease for which no disease-modifying drugs are available. Philochem AG and ETH Zurich will develop novel immunocytokines and evaluate delivery and screening systems to select the best candidate for the clinical development of a groundbreaking OA therapy.